Literature DB >> 2503031

Agonist-dependent generation of lipoxins from rat basophilic leukemia cell (RBL-1).

C F Ng1, B K Lam, K A Pritchard, M B Stemerman, P Hejny, P Y Wong.   

Abstract

Incubation of RBL-1 cells in the presence of 15-HPETE and various agonists generated lipoxins and several isomers. Addition of either A23187, fMLP or PMA modulated the number of isomers and amount of lipoxins produced. Administration of A23187 yielded the largest amount of product (5.3 +/- 1.6 micrograms per 10(8) cells) and generated a total of six and three isomers of LXA4 and B4, respectively. This was 2-fold greater than fMLP, which produced a total of two isomers of LXA4 and LXB4. Addition of PMA generated only LXA4 (0.68 +/- 0.26 micrograms). This is similar to the control receiving only 15-HPETE. Biologically derived LXA4 (3 nM) isolated from RBL-1 incubations contracted a rat tail artery preparation to 12% of the maximum induced by phenylephrine (0.125 microM), whereas LXA4 standard (3 nM) elicited 17.6% of the maximum contraction. These results indicate that RBL-1 cells can utilize exogenous 15-HPETE to generate biologically active lipoxins. Further, the yield and isomers of lipoxins can be modified by different agonists.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2503031     DOI: 10.1016/0005-2760(89)90081-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

Review 1.  Lipoxins: eicosanoids carrying intra- and intercellular messages.

Authors:  C N Serhan
Journal:  J Bioenerg Biomembr       Date:  1991-02       Impact factor: 2.945

2.  A novel rat lipoxin A4 receptor that is conserved in structure and function.

Authors:  Nan Chiang; Tomoko Takano; Makoto Arita; Shiro Watanabe; Charles N Serhan
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

3.  Primary human airway epithelial cell-dependent inhibition of human lung mast cell degranulation.

Authors:  Neil Martin; Andrew Ruddick; Greer K Arthur; Heidi Wan; Lucy Woodman; Christopher E Brightling; Don J L Jones; Ian D Pavord; Peter Bradding
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.